Context Therapeutics

What Context Therapeutics does

Context Therapeutics Inc. (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company headquartered in Philadelphia, Pennsylvania, founded in 2015. The company develops T cell engaging (TCE) bispecific antibodies for solid tumors and currently operates with a lean team of 1-10 employees. Context has shifted its strategic focus from its original women's oncology asset (onapristone extended release / ONA-XR) to a portfolio of three next-generation bispecific antibody candidates: CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3). All three candidates use an IgG format with silenced Fc domains and are engineered to be functionally monovalent to avoid aberrant T-cell activation; CT-202 additionally incorporates BioAtla's pH-dependent Conditionally Active Biologic (CAB) technology for tumor microenvironment selectivity. CTIM-76 was developed using Integral Molecular's MPS antibody discovery platform to isolate rare, highly selective CLDN6 antibodies that avoid cross-reactivity with other CLDN family members.

The pipeline targets multiple solid tumor indications including platinum-resistant ovarian cancer, endometrial, testicular, pancreatic, non-small cell lung, colorectal, triple-negative breast, mesothelioma, and urothelial cancers. CTIM-76 received FDA Fast Track Designation for platinum-resistant ovarian cancer in April 2026, and interim Phase 1 data released in June 2026 showed a 29% confirmed overall response rate and 57% disease control rate in heavily pretreated patients (median 7 prior lines of therapy), with cytokine release syndrome limited to Grade 1 in 11% of patients. All product candidates remain investigational; patient access is provided exclusively through enrollment in company-sponsored Phase 1 clinical trials (NCT06515613, NCT06756035, NCT07545122) and investigator-sponsored trials.

Context's business model is pre-revenue and oriented toward future licensing/royalty income. The company is funded through capital markets, most recently a $100 million private placement completed in May 2024 (lead investor Nextech1, with Ally Bridge Group, Blackstone, Avidity Partners, Blue Owl, Deep Track Capital, Driehaus Capital Management, and Great Point Partners participating). Cash and cash equivalents stood at $66.0 million as of December 31, 2025 (down from $94.4 million at year-end 2024), with management stating the runway extends into mid-2027. The company reported a 2025 net loss of $36.1 million on R&D expenses of $31.9 million, reflecting ramped clinical activity. A legacy exclusive license with Tyligand Bioscience grants Tyligand rights to ONA-XR in China, Hong Kong, and Macau, with Context eligible for royalties on net sales. Market capitalization was approximately $217.75 million as of April 2026, with a consensus 12-month price target of $6.60 from nine research firms.

Name

Context Therapeutics

Legal name

Context Therapeutics Inc.

Website

https://contexttherapeutics.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202) targeting solid tumors including ovarian, pancreatic, lung, breast, and urothelial cancers.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAAAAAF

Bispecific & Multispecific Antibodies

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

SECONDARYHLAAAIAB

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Bispecific antibody therapeutics
• T cell engager oncology
• Solid tumor immunotherapy
• Clinical stage biopharmaceutical
• Targeted cancer therapy

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. No Commercial Revenue: Context Therapeutics is a clinical-stage biopharmaceutical company with no commercialized products and no current revenue. All product candidates are investigational and have not received regulatory approval. Revenue will depend on successful development and commercialization of its bispecific antibody pipeline.

Distribution channels2 records

Marketing channels4 records

Core offering

Context Therapeutics develops T cell engaging (TCE) bispecific antibody therapies that bridge tumor cells with T cells to drive immune-mediated killing of solid tumor cancers. Its clinical pipeline comprises three investigational candidates: CTIM-76 (Claudin 6 x CD3), CT-95 (Mesothelin x CD3), and CT-202 (Nectin-4 x CD3), all engineered in an IgG format with silenced Fc for functional monovalency and improved safety. All product candidates are investigational and not yet commercially available.

Product overview

Context Therapeutics is a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibody therapies for solid tumors. The company's pipeline consists of three clinical-stage bispecific antibody product candidates: CTIM-76 (Claudin 6 x CD3), CT-95 (Mesothelin x CD3), and CT-202 (Nectin-4 x CD3). These TCEs are engineered antibodies designed to bridge tumor cells with T cells to activate immune-mediated cancer cell killing.

Differentiator

Problem solved

Functional benefit

Brands

• CTIM-76: CLDN6 x CD3 bispecific antibody for solid tumors
• CT-95
• CT-202

Products and services

• CTIM-76 CTIM-76 is an investigational Claudin 6 (CLDN6) x CD3 bispecific T cell engaging antibody being developed for solid tumors including ovarian, endometrial, testicular, and gastric cancers. It incorporates a highly selective CLDN6 binding arm developed using Integral Molecular's MPS antibody discovery platform, paired with a CD3 binding scFv domain in an IgG format with silenced Fc to drive T cell-mediated tumor cell killing.
• CT-95 CT-95 is an investigational mesothelin (MSLN) x CD3 bispecific T cell engaging antibody being developed for MSLN-positive solid tumors including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, non-small cell lung cancer, and triple-negative breast cancer. It features moderate-affinity MSLN binding arms designed to overcome shed mesothelin through membrane-proximal antigen binding.
• CT-202 CT-202 is an investigational Nectin-4 x CD3 bispecific T cell engaging antibody being developed for Nectin-4-positive solid tumors including bladder, non-small cell lung, colorectal, breast, and head and neck cancers. It incorporates BioAtla's Conditionally Active Biologic (CAB) pH-dependent binding technology that drives activity to the tumor microenvironment while minimizing binding to healthy tissues.

Quantifiable outcome

• 29% confirmed overall response rate in heavily pretreated platinum-resistant ovarian cancer patients (median 7 prior lines of therapy) with 57% disease control rate
• +4 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Tyligand BiosciencecoreOEM/ Whitelabel/ Licensing Partner · 25 August 2021Context Therapeutics and Tyligand Bioscience entered into a license agreement in August 2021, granting Tyligand exclusive rights and sole responsibility for development and commercialization of ONA-XR in China, Hong Kong, and Macau. Context retains rest of world rights and is eligible to receive royalties on net sales. Tyligand had previously completed ONA-XR manufacturing process optimization in collaboration with Context.
• Jefferson HealthminorStrategic or Co-development Partner · 12 May 2021Jefferson Health and Context Therapeutics collaborated on a Phase 2 clinical trial of ONA-XR in advanced endometrial cancer, with Jefferson Health dosing the first patient. Context has since shifted strategic focus to T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
• Integral MolecularcoreTechnology or IntegrationContext Therapeutics utilized Integral Molecular's MPS (Membrane Protein Scaffold) antibody discovery platform to isolate and optimize rare antibodies against CLDN6 that do not cross-react with other CLDN family members. This platform technology was critical to the development of CTIM-76's highly selective CLDN6 binding arm.
• BioAtlacoreTechnology or IntegrationCT-202 incorporates BioAtla's Conditionally Active Biologic (CAB) technology that uses pH dependency to drive localized antibody activity to the tumor microenvironment, minimizing binding to healthy tissues.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Janux Therapeutics: Clinical-stage immuno-oncology company developing T cell engager (TCE) bispecific antibodies for solid tumors using its proprietary TRACTr platform. Janux is one of the closest publicly traded pure-play peers to Context's TCE bispecific strategy.
• Harpoon Therapeutics: Developed T cell engaging trispecific and bispecific antibodies for solid tumors (e.g., HPN328, HPN217) using its TriTAC and ProTriTAC platforms; acquired by Merck for ~$680M in March 2024. Harpoon is a direct comparable and its former CMO (Luke Walker) is on Context's board.
• Maverick Therapeutics: Developed CONDITIONAL bispecific T cell engagers designed to be activated only in the tumor microenvironment, addressing the same solid-tumor selectivity challenges Context targets with CT-202's CAB technology.
• Cullinan Oncology: Clinical-stage oncology company developing multiple modalities including TCE bispecifics and immune-engaging antibodies for solid tumors, with a similar profile of small-cap, multi-asset, platform-driven development.
• CytomX Therapeutics: Clinical-stage oncology company developing Probody therapeutics, including masked T cell engaging bispecifics designed to be activated preferentially in the tumor microenvironment — directly analogous to Context's tumor-selective engineering approaches.
• Adagene: Clinical-stage immuno-oncology company developing TCE bispecifics using its POWERbody platform for conditional activation in tumors, with overlapping solid-tumor focus areas (including MSLN).
• MacroGenics: Clinical-stage biopharmaceutical company developing bispecific antibodies for cancer, including DART and TRIDENT platforms. Has multiple solid-tumor bispecific programs and serves as a direct small/mid-cap comparable for Context.

Broad incumbents

• Amgen: Established biopharmaceutical company and pioneer of the BiTE (bispecific T cell engager) platform, with approved assets Blincyto (CD19 x CD3) and Imdelltra (DLL3 x CD3). Amgen is a broad incumbent with far greater resources and represents the most significant competitive threat in solid-tumor TCEs.
• Xencor: Clinical-stage company developing engineered antibody therapeutics including bispecifics via its XmAb platform. Xencor is a broad incumbent in bispecific antibody engineering, with multiple partnered and wholly-owned oncology bispecific programs in solid tumors.
• AstraZeneca: Global biopharmaceutical company with a significant oncology franchise and active bispecific antibody development, including TCEs and tumor-targeted immunotherapies. Represents a broad incumbent competitor and potential strategic acquirer of Context's pipeline.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/context_tx
• LinkedInlinkedin.com/company/context-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Context Therapeutics